New perspectives for the diagnosis and treatment of oligodendroglioma

Expert Review of Anticancer Therapy

Volumn 1, Issue 3, 2001, Pages 348-356

  van den Bent, Martin J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

1p; Chemotherapy; Chromosomal lesions; MGMT; Oligoastrocytoma; Oligodendroglioma; PCV; Prognosis; Radiation therapy; Temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; PACLITAXEL; PROCARBAZINE; TEMOZOLOMIDE; THIOTEPA; VINCRISTINE;

ADULT; ASTROCYTOMA; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER GRADING; CANCER RECURRENCE; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GLIOMA; HUMAN; MALE; MOLECULAR BIOLOGY; OLIGODENDROGLIOMA; PATIENT SELECTION; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0035559912     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.3.348     Document Type: Review

References (70)

1. Oligodendroglioma: Incidence and biological behavior in a defined population
2. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas
3. Successfull chemotherapy for recurrent oligodendroglioma
4. Chemotherapy for anaplastic oligodendroglioma
5. Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy
6. Oligodendroglioma
7. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype
8. Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading
9. Oligodendroglioma: A comparison of two grading systems
10. Oligodendrogliomas: The Mayo Clinic experience
11. Grading of oligodendrogliomas
12. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas
13. Oligodendroglioma: The Rotterdam-Dijkzigt Experience
14. Cerebral oligodendroglioma: Prognostic factors and life history
15. The prognostic role of vessel productive changes and vessel density in oligodendroglioma
16. The prognostic significance of K1-67 labeling indices for oligodendrogliomas
17. Proliferating cell neuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis
18. Prognostic factors in oligodendroglioma
19. Oligoastrocytomas: A clinicopathological study of 52 cases
20. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
21. Molecular genetic evidence for subtypes of oligoastrocytomas
22. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization
23. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p
24. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
25. Demonstration of p53 protein and TP53 genemutations in oligodendrogliomas
26. PTEN Mutation analysis in two genetic subtypes of high-grade oligodendroglial tumours: PTEN is only occasionally mutated in one of the two genetic subtypes
27. Molecular characterization of glioblastoma with oligodendroglial component
28. A clinicopathological study of 323 patients with oligodendrogliomas
29. Intracranial oligodendrogliomas: Imaging findings in 35 untreated cases
30. Oligodendroglioma. An analysis of the value of radiation therapy
31. Oligodendroglioma. The Princess Margaret Hospital Experience (1958-1984)
32. The role of postoperative irradiation in the treatment of Oligodendroglioma
33. Oligodendroglioma: An analysis of 42 cases
34. Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria
35. Allelic loss of chromosome 1p predicts long term progression free survival after radiotherapy in patients with oligodendroglioma
36. Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis
37. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: A report of radiation therapy oncology group 83-02
38. Mixed oligoastrocytomas: A survival and prognostic factor analysis
39. Supratentorial low-grade glioma in adults: An analysis of prognostic factors and the timing of radiation
40. Treatment of oligodendrogliomas with or without postoperative irradiation
41. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas
42. Neoadjuvant procarbazine, CCNU and vincristine for anaplastic and aggresive oligodendroglioma
43. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors
44. Low-grade oligodendroglioma responds to chemotherapy
45. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy
46. Chemotherapy for low-grade oligodendrogliomas?
47. Chemotherapy with PCV for low grade nonenhancing oligodendrogliomas and oligoastrocytomas
48. PCV chemotherapy in low grade non-enhancing oligodendroglioma
49. Role of chemotherapy in oligodendroglial tumors: A review of the experience at the University of Torino
50. Salvage chemotherapy for oligodendroglioma
51. Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas
52. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
53. Temozolomide chemotherapy in recurrent oligodendroglioma
54. EORTC study 26972: Second line temozolomide chemotherapy in recurrent oligodendroglial tumors after prior PCV chemotherapy: A Phase II study
55. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy
56. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma
57. The treatment of anaplastic oligodendrogliomas and mixed gliomas
58. Aggressive oligodendroglioma: A chemosensitive tumor
59. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: A southwest oncology group study
60. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
61. O6 methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage
62. Glial cell-specific differences in repair of O6-methylguanine
63. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages with differential response of oligodendrogliomas and astrocytomas to chemotherapy
64. O6-methylguanine-DNA methyltransferase activity in adult gliomas: Relation to patient and tumor characteristics
65. Immunohistochemical staining for alkyltransferase does not predict response to PCV chemotherapy in oligodendroglial tumors
66. Long-term outcome of low-grade oligodendroglioma and mixed glioma
67. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas
68. Immediate postoperative radiotherapy in low grade glioma improves progression free survival, but not overall survival: Preliminary results of an EORTC/MRC randomized Phase III study
69. A randomized trial on dose-response in radiation therapy of low grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 2284
70. A prospective randomized trial of low versus high dose radiation in adults with a supratentorial low grade glioma: Initial report of a NCCTG-RTOG-ECOG study